New antibody treatment offers hope for rare blistering skin disease
NCT ID NCT06900010
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called CM336 in 30 adults with moderate to severe autoimmune bullous disease, a condition where the immune system attacks the skin causing painful blisters. The drug targets specific immune cells to reduce this attack. The main goal is to see if the drug can help patients achieve lasting remission.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE BULLOUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dermatology Hospital Affiliated to Shandong First Medical University
RECRUITINGJinan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Study reveals bone risks from common skin treatment
- Scientists probe hidden clot risks in autoimmune skin disorders
- Experimental CAR-T injection aims to tame autoimmune diseases
- New study tests easier treatment for blistering skin disease
- New drug B007 aims to tame pemphigus with fewer meds
- One-Dose hope for blistering skin disease?